ADMA Biologics (NASDAQ:ADMA) Receives Overweight Rating from Cantor Fitzgerald

ADMA Biologics (NASDAQ:ADMA)‘s stock had its “overweight” rating restated by equities researchers at Cantor Fitzgerald in a research note issued on Friday, Benzinga reports. They presently have a $20.00 target price on the biotechnology company’s stock. Cantor Fitzgerald’s target price suggests a potential upside of 0.10% from the company’s current price.

ADMA has been the topic of a number of other research reports. Mizuho lifted their price target on ADMA Biologics from $12.00 to $14.00 and gave the stock a “buy” rating in a research note on Thursday, June 20th. HC Wainwright lifted their target price on shares of ADMA Biologics from $10.00 to $18.00 and gave the stock a “buy” rating in a research report on Monday, August 12th. One research analyst has rated the stock with a hold rating, three have issued a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Buy” and a consensus price target of $15.50.

ADMA Biologics Trading Up 1.2 %

Shares of NASDAQ:ADMA opened at $19.98 on Friday. The company has a debt-to-equity ratio of 0.74, a quick ratio of 2.80 and a current ratio of 6.87. The stock has a market capitalization of $4.63 billion, a price-to-earnings ratio of -999.00 and a beta of 0.61. ADMA Biologics has a 1-year low of $3.06 and a 1-year high of $20.16. The company has a 50 day moving average price of $15.77 and a 200 day moving average price of $10.96.

ADMA Biologics (NASDAQ:ADMA) last released its quarterly earnings data on Thursday, August 8th. The biotechnology company reported $0.13 earnings per share for the quarter, topping the consensus estimate of $0.08 by $0.05. The business had revenue of $107.20 million during the quarter, compared to analyst estimates of $86.44 million. ADMA Biologics had a return on equity of 38.79% and a net margin of 10.53%. The company’s revenue was up 78.4% compared to the same quarter last year. During the same period last year, the company posted ($0.02) EPS. On average, research analysts anticipate that ADMA Biologics will post 0.49 EPS for the current fiscal year.

Insider Activity

In other news, Director Young Kwon sold 60,000 shares of the stock in a transaction that occurred on Friday, August 23rd. The shares were sold at an average price of $18.26, for a total value of $1,095,600.00. Following the completion of the sale, the director now directly owns 241,441 shares of the company’s stock, valued at $4,408,712.66. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. In related news, Director Young Kwon sold 60,000 shares of ADMA Biologics stock in a transaction on Friday, August 23rd. The stock was sold at an average price of $18.26, for a total transaction of $1,095,600.00. Following the completion of the sale, the director now owns 241,441 shares of the company’s stock, valued at $4,408,712.66. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, CEO Adam S. Grossman sold 236,889 shares of the company’s stock in a transaction dated Monday, August 26th. The stock was sold at an average price of $17.69, for a total value of $4,190,566.41. Following the completion of the transaction, the chief executive officer now directly owns 2,059,726 shares in the company, valued at $36,436,552.94. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 466,900 shares of company stock worth $8,224,121. 3.70% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On ADMA Biologics

Several hedge funds and other institutional investors have recently added to or reduced their stakes in ADMA. Mesirow Institutional Investment Management Inc. bought a new stake in ADMA Biologics in the first quarter worth approximately $17,221,000. Bank of Montreal Can bought a new stake in ADMA Biologics in the second quarter worth $17,886,000. D. E. Shaw & Co. Inc. increased its position in ADMA Biologics by 26.8% during the second quarter. D. E. Shaw & Co. Inc. now owns 6,824,517 shares of the biotechnology company’s stock worth $76,298,000 after buying an additional 1,442,799 shares during the last quarter. Castleark Management LLC acquired a new position in ADMA Biologics during the first quarter worth $5,400,000. Finally, Hillsdale Investment Management Inc. raised its holdings in ADMA Biologics by 41,893.3% during the first quarter. Hillsdale Investment Management Inc. now owns 629,900 shares of the biotechnology company’s stock valued at $4,157,000 after buying an additional 628,400 shares in the last quarter. Institutional investors own 75.68% of the company’s stock.

About ADMA Biologics

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.